OCUP Nasdaq

Ocuphire Pharma Inc.

OCUP | $1.67 -4.02% -3.88% 19

(0.0% 1d) (-15.7% 1m) (-72.9% 1y) (0.0% 2d) (-4.0% 3d) (-5.1% 7d) (159.31% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 41,438,328
http://www.ocuphire.com
Sec Filling | Patents | 5 employees

(US) Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

eye treatment

add to watch list Paper trade email alert is off

Press-releases

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
Published: 2024-04-11 (Crawled : 14:00) - globenewswire.com
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -10.22% | O: -1.08% H: 1.63% C: -2.72%
first solution light treatment for study

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
VTRS | $11.12 0.18% 0.09% 130

Health Technology

| -6.32% | O: 0.84% H: 0.0% C: -0.25%
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -16.5% | O: 1.0% H: 10.4% C: 10.4%
solution commercial ryzumvl apx3330

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Published: 2024-03-08 (Crawled : 13:00) - globenewswire.com
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -29.83% | O: -1.26% H: 0.0% C: -15.32%
pharma year update financial results

Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Published: 2024-02-23 (Crawled : 13:00) - globenewswire.com
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -33.2% | O: 0.8% H: 0.34% C: -0.79%
pharma ceo conference

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -36.98% | O: -0.75% H: 3.07% C: 0.0%
pharma nasdaq grants

Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
DERM | $3.58 2.1K

| -15.56% | O: 0.0% H: 3.78% C: -0.89%
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -35.02% | O: 0.0% H: 2.14% C: 1.17%
pharma key

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
OCUP | $1.67 -4.02% -3.88% 19

Health Technology

| -36.98% | O: 0.75% H: 0.37% C: -5.62%
apx3330 pharma conference presentation

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-24 (Crawled : 21:00) - globenewswire.com
OCUP | $1.67 -4.02% -3.88% 19

Health Technology